Results 71 to 80 of about 861 (122)

Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration [PDF]

British Journal of Ophthalmology, 2016
In vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using intravitreal ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in wet age-related macular degeneration (AMD) treated with intravitreal ziv-aflibercept.Prospectively, consecutive patients with wet AMD underwent ziv-aflibercept ...
Ahmad M, Mansour, Jay, Chhablani, Rafic S, Antonios, Rohit, Yogi, Muhammad H, Younis, Rola, Dakroub, Hasan, Chahine   +6 more
openaire   +2 more sources

Efficacy of intravitreal injection of Ziv-aflibercept before vitrectomy for proliferative diabetic retinopathy

Delta Journal of Ophthalmology
Purpose The aim of this study was to evaluate the efficacy of intravitreal injection of Ziv-aflibercept before small-gauge pars plana vitrectomy compared to pars plana vitrectomy alone in eyes with advanced diabetic eye disease. Patients and methods
Amin E. Nawar, Ahmed R. Alagorie
doaj   +1 more source

Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer

World Journal of Clinical Oncology, 2014
Ziv-afilbercept (Zaltrap, Ziv) is a humanized fusion protein constructed by joining the vascular endothelial growth factor (VEGF) binding portions of human VEGF receptors 1 and 2 to the Fc portion of human immunoglobulin IgG1. Recently, a randomized, open-label, phase III study compared 5-fluorouracil, leucovorin, irinotecan (FOLFIRI)/Ziv with FOLFIRI ...
Muhammad Wasif, Saif, Valerie, Relias, Kostas, Syrigos, Krishna S, Gunturu   +3 more
openaire   +2 more sources

Ziv-aflibercept in metastatic colorectal cancer

Biologics: Targets & Therapy, 2013
Anuj Patel, Weijing Sun Division of Hematology-Oncology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Abstract: The combination of cytotoxic chemotherapy and antiangiogenic agents has become
Patel A, Sun W
doaj  

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial

Clinical Ophthalmology, 2023
Suthasinee Sinawat,1,2 Suthasinee Hemanak,1 Kwanchanok Chanthowong,1 Supat Sinawat,3 Yosanan Yospaiboon1,2 1Department of Ophthalmology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; 2KKU Eye Center, Khon Kaen University, Khon Kaen ...
Sinawat S, Hemanak S, Chanthowong K, Sinawat S, Yospaiboon Y   +4 more
doaj  

To laser or not?

Indian Journal of Ophthalmology, 2018
A 64-year-old male patient presented to the clinic with diminished vision in his right eye for the past 2 years. Examination revealed a best-corrected visual acuity (BCVA) of counting fingers at 1 m with a scarred choroidal neovascular membrane (CNVM) in
Vishal Govindhari, Jay Chhablani
doaj   +1 more source

Role of Optical Coherence Tomography-angiography in Diagnosis and Monitoring Activity of Macular Telangiectasia-associated Choroidal Neovascular Membrane

Delhi Journal of Ophthalmology
We report the case of a 62-year-old female diagnosed with Type 2A, Stage 5 macular telangiectasia (MacTel). The right eye showed a scarred choroidal neovascular membrane (CNVM) while the left eye had an active CNVM, confirmed with optical coherence ...
Mohd Azaz Quraishi, Pratik Shenoy, Onkar H. Pirdankar, Amit S. Nene, Pushpanjali Badole, Smitesh Shah   +5 more
doaj   +1 more source

Intravitreal Ziv-Aflibercept versus Bevacizumab for Naïve Central Retinal Vein Occlusion with Macular Edema: An Interim Analysis of a Randomized Non-Inferiority Trial. [PDF]

Clin Ophthalmol, 2023
Sinawat S, Hemanak S, Chanthowong K, Sinawat S, Yospaiboon Y.   +4 more
europepmc   +1 more source

Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?

Cancer Management and Research, 2013
Muhammad Wasif Saif GI Oncology Program, Tufts University School of Medicine, Boston, MA, USA Abstract: Bevacizumab is a monoclonal antibody that binds and neutralizes vascular endothelial growth factor (VEGF)-A, a key player in the angiogenesis pathway.
Saif MW
doaj  

Three-Month Outcome of Ziv-Aflibercept for Diabetic Macular Edema

Advances in Ophthalmology & Visual System, 2016
1.1.Purpose:Is to show the 3-month efficacy and safety of treatment diabetic macular edema treated with intravitreal ziv-aflibercept as studies have shown that Ziv-aflibercept does not cause retinal pigment epithelial toxicity and to study it cost effectiveness.
openaire   +1 more source